Together, the two organizations will collaborate on helping expand access to innovative healthcare solutions that are available both in and outside of China to ultimately help more patients globally discover new treatment options for a variety of disease states.
Buoyed by the success of its diabetes and obesity drugs, Novo Nordisk is on the prowl for partnerships and deals to beef up its pipeline, a senior company executive said on Thursday.
The latest acquisition expands Spectrum’s global capabilities, and provides enhanced resources, expertise and experience to award-winning Aurora team.
Therapeutics isn’t into exercises in futility. The Bay area-based biopharma company is discontinuing enrollment in two arms of its three-arm Phase II study of praluzatamab ravtansine in patients with triple-negative breast cancer (TNBC) after those studies failed to meet the protocol-defined futility boundary.
Evotec SE is on a deal-making spree. The company just inked another contract, this time with Janssen Pharmaceutical that showcases Evotec’s end-to-end integrated drug discovery and development platform.
Today, Evoke announces the integration of Ashfield Health marketing and communications agencies to form a new global healthcare brand, experience and communications platform, purpose-built to make health more human. The combination of two leading global healthcare organizations in one agile platform under the Evoke name creates one of the industry’s deepest and most dynamic marketing and communications offerings.